Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Inclusion Criteria:

• Has confirmed diagnosis of systemic sclerosis with onset of disease ≤ 5 years ago.

• Has diffuse cutaneous scleroderma

• Has systemic sclerosis related interstitial lung disease confirmed by HRCT

• FVC ≥ 45% of predicted normal

• Diffusing capacity of lung for carbon monoxide (DLCO)≥ 45% of predicted normal

• If on background therapy, meets stable dosing requirements for nintedanib,mycophenolate mofetil (MMF), methotrexate (MTX) OR azathioprine, and corticosteroids

• Women of childbearing potential are eligible to participate if not pregnant orbreastfeeding and either willing to use an acceptable contraceptive method orsexually abstinent

• Able to provide written informed consent and understand and comply with therequirements of the study

Exclusion Criteria:

• Has an airway obstruction per pulmonary function test (PFT) or clinicallysignificant pulmonary arterial hypertension

• Has current clinical diagnosis of another inflammatory connective tissue disease

• Has any active infections, a serious infection within the past 3 months, or chronicbacterial infection

• Is a current smoker or smoking within 6 months of screening

• Has any concomitant medical conditions that, in the opinion of the investigator,might place them in unacceptable risk for participation in the study

• Meets the protocol criteria for important laboratory exclusion criteria